The in vitro antimicrobial activity of iclaprim, a novel diaminopyrimidine, against common respiratory bacteria remained unchanged in the presence of pulmonary surfactant (Survanta ® ) at concentrations that greatly antagonized the antimicrobial activity of daptomycin. These results indicate that iclaprim could be a potential treatment for pneumonia caused by susceptible and multidrug resistant bacteria.
Introduction
Iclaprim represents a novel diaminopyrimidine, which inhibits bacterial dihydrofolate reductase (DHFR) and is active against emerging drug-resistant pathogens (Sader et al., 2009; Schneider et al., 2003) . Iclaprim exhibits potent in vitro activity against Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and atypical bacteria (i.e., Legionella pneumophila, Chlamydia pneumoniae, and Mycloplasma pneumoniae) that cause pneumonia (Sader et al., 2009; Morrissey et al., 2009) . Iclaprim demonstrates rapid in vitro bactericidal activity in time kill studies in human plasma (Laue et al., 2009 ). Because of these findings, iclaprim is potentially well suited for treating patients with nosocomial pneumonia caused by susceptible and multidrug resistant pathogens. In the present study, we investigated the effect of bovine pulmonary surfactant (BPS), a major component of epithelial lining fluid, on the antibacterial activity of iclaprim against common Gram-positive and Gramnegative respiratory bacteria in vitro.
Methods

Collection of bacterial isolates
Clinical isolates were identified by the submitting laboratories and confirmed by JMI Laboratories using standard bacteriologic algorithms and methodologies, including MatrixAssisted Laser Desorption Ionization-Time Of Flight Mass Spectrometry (MALDI-TOF MS).
When necessary, MALDI-TOF MS was performed using the Bruker Daltonics MALDI Biotyper (Billerica, Massachusetts, USA), following manufacturer's instructions. Isolates selected were from bacterial species commonly associated with pneumonia. The clinical isolates were S.
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4 pneumoniae (n=2), H. influenzae (n=1), M. catarrhalis (n=2), S. aureus (n=1), and Klebsiella pneumoniae (n=1). Table 2 shows the seven American Type Culture Collection (ATCC) reference strains that were tested. The 14 isolates and strains in this study were similar to the numbers examined in prior studies of the effect of surfactant on in vitro activity of antimicrobials (Dallow et al, 2014 (n=18) ; Glacobbe et al 2017 (n=7); Gotfried et al, 2008 (n=2) ). The specific isolates were chosen because they were recent clinical isolates from species associated with pulmonary infections; the reference strains are frequently used ATCC QC reference strains.
Susceptibility testing
Antibacterial susceptibility testing was measured by JMI Laboratories (North Liberty, Iowa, USA). The seven nonduplicative, nonconsecutive clinical isolates were collected from US (n=4), Mexico (n=1), and Italy (n=2). Susceptibility testing was performed by broth microdilution in accordance with the Clinical and Laboratory Standards Institute (CLSI) guidelines M07-A10 (2015) and the standard operating procedures at JMI Laboratories.
Minimum inhibitory concentrations (MICs) were based on CLSI criteria (2015) . There are no published breakpoints for iclaprim, which is typical for drugs in development. E. coli, K.
pneumoniae, M. catarrhalis, E. faecalis, and S. aureus were tested in cation-adjusted MuellerHinton broth (CA-MHB). S. pneumoniae was tested in CA-MHB supplemented with 2.5-5% lysed horse blood, and H. influenzae was tested in Haemophilus Test Medium. Quality control ranges and interpretation of results were performed in accordance with CLSI M100-S26 (2016) methods. QC ranges for iclaprim were those approved by CLSI and published in M100-S26
(2016).
Because bovine pulmonary surfactant can introduce cloudiness to the MIC testing media,
antimicrobial growth inhibition was also evaluated using the colorimetric metabolic indicator resazurin (Camlab Ltd., Cambridge, UK). Following visual MIC value determinations, 10 µL of a resazurin solution (6.75 -7.0 mg/mL in H 2 O) was added to the test wells in each panel, and the panels were incubated for an additional 1-3 hours at 35˚C in ambient atmosphere (Elshikh et al., 2016; Sarker et al., 2007) . S. pneumoniae panels were omitted from resazurin analysis because the color change was obscured by the lysed horse blood present in the test medium. Growth inhibition was then evaluated as a visible color change from blue (no growth) to pink (robust growth) and recorded as a MIC RZ value.
Pulmonary surfactant interaction
The MICs of iclaprim, levofloxacin, and daptomycin were measured against Grampositive and Gram-negative isolates. Daptomycin was included as a positive control and levofloxacin was included as a negative control because published data showed an increase in daptomycin MICs but no increase in levofloxacin MICs in the presence of pulmonary surfactant (Silverman et al, 2005; Giacobbe et al, 2017) .
A new vial of bovine pulmonary surfactant (BPS; Survanta ® ; Abbott Laboratories, Columbus, OH) was utilized for each independent experiment. Each vial was mixed thoroughly and a 100 µL aliquot was spread on an agar growth plate, which was incubated overnight to confirm sterility. BPS was added to the MIC test medium to a final concentration of 2.5% (v/v).
The concentration of surfactant was expressed in terms of percent volume of Survanta ® suspension, which consisted of phospholipid (25 mg/mL) and surfactant proteins (<1 mg/mL) in 0.9% sodium chloride solution (Goerke, 1998) . The concentration of 2.5% was chosen because the effect of BPS on S. aureus daptomycin MIC values plateaus above approximately 1%
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6 (Silverman et al, 2005; Dallow et al, 2014; Gotfriend et al, 2008) and because MIC values become difficult to read using CLSI methodology above 2.5%. MICs of daptomycin were determined in CAMHB with the Ca 2+ content adjusted to 50 mg/L. µg/mL in the presence of 2.5% BPS, consistent with published data (Dallow et al., 2014; Silverman et al. 2005) . As expected, the presence of BPS had little or no effect on the MIC and MIC RZ values of levofloxacin (see Table 1 ).
Results
Pulmonary surfactant interaction
Discussion
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In summary, this report demonstrates that iclaprim is active in vitro against common respiratory bacterial pathogens (S. pneumoniae, H. influenzae, S. aureus, K. pneumoniae and M.
catarrhalis) even in the presence of pulmonary surfactant. In contrast, the inhibitory effect of surfactant on antibacterial activity was observed with daptomycin. This inhibitory MIC effect of surfactant on daptomycin activity has been reported to be mediated by binding of surfactant components to specific structures present on antibiotics, such as the the lipophilic side-chain of daptomycin (Silverman et al., 2005) . Thus, unlike daptomycin, the potency of iclaprim against common respiratory bacterial pathogens and the absence of antagonism by pulmonary surfactant against iclaprim shown in this in vitro study suggests that iclaprim should be active against pulmonary pathogens in pneumonia in vivo.
A Phase 1 study investigated the tissue distribution of a single IV dose of iclaprim in relevant lung compartments (Andrews et al, 2007) . iclaprim q8h, and vancomycin groups, respectively (no statistically significant differences).
Collectively, the current in vitro study, and previous Phase 1 and 2 studies support that iclaprim could be a potential treatment for pneumonia, including nosocomial pneumonia caused by susceptible and multidrug resistant Gram-positive bacteria. 
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